Hepion Pharmaceuticals, Inc. SEC filings CTRVP
Hepion Pharmaceuticals, Inc. has 723 filings in SEC EDGAR's recent list, going back to Aug 8, 2013. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 9, 2026 (material agreement, acquisition or sale of assets, unregistered share sale, officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 4 | Insider transaction | Oct 27, 2026 | Oct 23, 2026 |
| 4 | Insider transaction | Oct 27, 2026 | Oct 23, 2026 |
| 4 | Insider transaction | Oct 27, 2026 | Oct 23, 2026 |
| 4 | Insider transaction | Oct 27, 2026 | Oct 23, 2026 |
| 4 | Insider transaction | Oct 27, 2026 | Oct 23, 2026 |
| 4 | Insider transaction | Oct 27, 2026 | Oct 23, 2026 |
| 4 | Insider transaction | Oct 27, 2026 | Oct 23, 2026 |
| 4 | Insider transaction | Oct 27, 2026 | Oct 23, 2026 |
| SCHEDULE 13D | Ownership over 5% (active) | Oct 26, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Oct 21, 2026 | — |
| 3 | Initial insider ownership | Oct 21, 2026 | Oct 6, 2026 |
| S-8 | Employee stock plan registration | Oct 14, 2026 | — |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Officer or director change
|
Oct 9, 2026 | Oct 6, 2026 |
| 4 | Insider transaction | Oct 2, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Oct 2, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Auditor change
|
Sep 28, 2026 | Sep 21, 2026 |
| 3 | Initial insider ownership | Sep 16, 2026 | Aug 3, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Sep 16, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Sep 15, 2026 | — |
| 4 | Insider transaction | Sep 14, 2026 | Sep 3, 2026 |
| DEF 14C | Information statement | Sep 10, 2026 | Sep 10, 2026 |
| 4 | Insider transaction | Sep 10, 2026 | Aug 19, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Sep 8, 2026 | Sep 3, 2026 |
| PRE 14C | Filing | Aug 31, 2026 | Aug 28, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Aug 27, 2026 | Aug 25, 2026 |
| 4 | Insider transaction | Aug 21, 2026 | Aug 19, 2026 |
| 4 | Insider transaction | Aug 21, 2026 | Aug 19, 2026 |
| 4 | Insider transaction | Aug 21, 2026 | Aug 19, 2026 |
| 4 | Insider transaction | Aug 21, 2026 | Aug 19, 2026 |
| 4 | Insider transaction | Aug 21, 2026 | Aug 19, 2026 |
| 4 | Insider transaction | Aug 21, 2026 | Aug 19, 2026 |
| 4 | Insider transaction | Aug 21, 2026 | Aug 19, 2026 |
| 3 | Initial insider ownership | Aug 21, 2026 | Aug 19, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 20, 2026 | Aug 19, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Aug 20, 2026 | — |
| SCHEDULE 13D | Ownership over 5% (active) | Aug 20, 2026 | — |
| SCHEDULE 13D | Ownership over 5% (active) | Aug 20, 2026 | — |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 4 | Insider transaction | Aug 12, 2026 | Aug 3, 2026 |
| 4 | Insider transaction | Aug 12, 2026 | Aug 3, 2026 |
| 4 | Insider transaction | Aug 12, 2026 | Aug 3, 2026 |
| 4 | Insider transaction | Aug 12, 2026 | Aug 3, 2026 |
| 4 | Insider transaction | Aug 12, 2026 | Aug 3, 2026 |
| 3 | Initial insider ownership | Aug 7, 2026 | Aug 3, 2026 |
| S-8 | Employee stock plan registration | Aug 7, 2026 | — |
| SCHEDULE 13D | Ownership over 5% (active) | Aug 7, 2026 | — |
| D | Filing | Aug 5, 2026 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Aug 4, 2026 | Jul 31, 2026 |
| 3 | Initial insider ownership | Jul 10, 2026 | Jul 1, 2026 |
| 3 | Initial insider ownership | Jul 8, 2026 | Jul 1, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 2, 2026 | Jul 1, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 17, 2026 | Jun 17, 2026 |
| 3 | Initial insider ownership | May 26, 2026 | Mar 16, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| SCHEDULE 13D | Ownership over 5% (active) | May 1, 2026 | — |
| ARS | Annual report to shareholders | Apr 28, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| DEF 14A | Proxy statement | Apr 28, 2026 | Apr 28, 2026 |
| 4 | Insider transaction | Apr 27, 2026 | Apr 21, 2026 |
| 4 | Insider transaction | Apr 27, 2026 | Apr 21, 2026 |
| 4 | Insider transaction | Apr 27, 2026 | Apr 21, 2026 |
| 4 | Insider transaction | Apr 27, 2026 | Apr 21, 2026 |
| D | Filing | Apr 22, 2026 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Apr 22, 2026 | Apr 21, 2026 |
| 8-K |
Current report
Material agreement, Officer or director change
|
Apr 14, 2026 | Apr 13, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 16, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 16, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 16, 2026 |
| 8-K |
Current report
Officer or director change
|
Mar 18, 2026 | Mar 16, 2026 |
| 10-K | Annual report | Mar 12, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Material agreement, Other events
|
Mar 3, 2026 | Feb 25, 2026 |
| 8-K |
Current report
Officer or director change
|
Jan 15, 2026 | Jan 3, 2026 |
| 10-Q | Quarterly report | Nov 12, 2025 | Sep 30, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2025 | — |
| 10-Q | Quarterly report | Aug 14, 2025 | Jun 30, 2025 |
| 25-NSE | Delisting notice | Jul 22, 2025 | — |
| 8-K |
Current report
Officer or director change
|
Jun 30, 2025 | Jun 25, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2025 | Jun 12, 2025 |
| 8-K |
Current report
Officer or director change
|
Jun 9, 2025 | Jun 3, 2025 |
| 8-K |
Current report
Material agreement
|
May 30, 2025 | May 26, 2025 |
| 10-Q | Quarterly report | May 19, 2025 | Mar 31, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | May 15, 2025 | — |
| NT 10-Q | Filing | May 15, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Listing notice
|
May 12, 2025 | May 9, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
May 6, 2025 | Apr 30, 2025 |
| ARS | Annual report to shareholders | Apr 29, 2025 | Dec 31, 2024 |
| DEF 14A | Proxy statement | Apr 28, 2025 | Apr 28, 2025 |
| UPLOAD | Letter from the SEC | Apr 24, 2025 | — |
| PRER14A | Filing | Apr 23, 2025 | — |
| 8-K |
Current report
Listing notice
|
Apr 17, 2025 | Apr 15, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 16, 2025 | Apr 16, 2025 |
| 10-K | Annual report | Apr 8, 2025 | Dec 31, 2024 |
| 8-K/A |
Amended current report
Other events
|
Apr 4, 2025 | Mar 4, 2025 |
| NT 10-K | Filing | Apr 1, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Listing notice
|
Mar 20, 2025 | Mar 18, 2025 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Mar 19, 2025 | Mar 17, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Mar 10, 2025 | Mar 10, 2025 |
| 8-K |
Current report
Other events
|
Mar 4, 2025 | Mar 4, 2025 |
| DEF 14A | Proxy statement | Feb 7, 2025 | Feb 7, 2025 |
| ARS/A | Filing | Feb 7, 2025 | Dec 31, 2023 |
| ARS | Annual report to shareholders | Feb 7, 2025 | Dec 31, 2023 |
| PRE 14A | Preliminary proxy statement | Jan 27, 2025 | Jan 27, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Jan 27, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Jan 24, 2025 | — |
| 424B4 | Prospectus | Jan 23, 2025 | — |
| EFFECT | Filing | Jan 21, 2025 | — |
| S-1MEF | Filing | Jan 21, 2025 | — |
| CORRESP | Letter to the SEC | Jan 17, 2025 | — |
| CORRESP | Letter to the SEC | Jan 17, 2025 | — |
| CORRESP | Letter to the SEC | Jan 15, 2025 | — |
| CORRESP | Letter to the SEC | Jan 15, 2025 | — |
| 8-K |
Current report
Listing notice
|
Jan 15, 2025 | Jan 14, 2025 |
| CORRESP | Letter to the SEC | Jan 14, 2025 | — |
| CORRESP | Letter to the SEC | Jan 14, 2025 | — |
| S-1/A | Amended registration statement | Jan 14, 2025 | — |
| 10-K/A | Amended annual report | Jan 13, 2025 | Dec 31, 2023 |
| UPLOAD | Letter from the SEC | Jan 2, 2025 | — |
| S-1 | Registration statement | Dec 26, 2024 | — |
| 8-K |
Current report
Agreement ended, Other events
|
Dec 11, 2024 | Dec 10, 2024 |
| DEFA14A | Additional proxy material | Dec 5, 2024 | — |
| DEFA14A | Additional proxy material | Dec 2, 2024 | — |
| 425 | Filing | Nov 21, 2024 | — |
| 8-K |
Current report
Listing notice
|
Nov 21, 2024 | Nov 20, 2024 |
| 10-Q | Quarterly report | Nov 14, 2024 | Sep 30, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 14, 2024 | — |
| 425 | Filing | Sep 5, 2024 | — |
| 8-K |
Current report
Listing notice
|
Sep 5, 2024 | Sep 3, 2024 |
| 10-Q | Quarterly report | Aug 13, 2024 | Jun 30, 2024 |
| 425 | Filing | Aug 7, 2024 | — |
| 8-K |
Current report
Officer or director change
|
Aug 7, 2024 | Aug 5, 2024 |
| D | Filing | Jul 24, 2024 | — |
| 425 | Filing | Jul 22, 2024 | — |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Officer or director change, Regulation FD disclosure, Other events
|
Jul 22, 2024 | Jul 19, 2024 |
| EFFECT | Filing | Jul 15, 2024 | — |
| 424B3 | Prospectus | Jul 15, 2024 | — |
| CORRESP | Letter to the SEC | Jul 12, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 12, 2024 | — |
| S-1 | Registration statement | Jul 11, 2024 | — |
| 10-K/A | Amended annual report | Jun 25, 2024 | Dec 31, 2023 |
| 10-Q | Quarterly report | May 21, 2024 | Mar 31, 2024 |
| NT 10-Q | Filing | May 15, 2024 | Mar 31, 2024 |
| 10-K | Annual report | Apr 16, 2024 | Dec 31, 2023 |
| NT 10-K | Filing | Apr 1, 2024 | Dec 31, 2023 |
| 4 | Insider transaction | Mar 7, 2024 | Mar 6, 2024 |
| 3 | Initial insider ownership | Mar 6, 2024 | Mar 5, 2024 |
| 8-K |
Current report
Officer or director change
|
Mar 6, 2024 | Mar 5, 2024 |
| 4 | Insider transaction | Feb 21, 2024 | Feb 19, 2024 |
| 4 | Insider transaction | Feb 21, 2024 | Feb 19, 2024 |
| 4 | Insider transaction | Feb 21, 2024 | Feb 19, 2024 |
| 4 | Insider transaction | Feb 21, 2024 | Feb 19, 2024 |
| 8-K |
Current report
Officer or director change
|
Feb 20, 2024 | Feb 20, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Feb 16, 2024 | Feb 15, 2024 |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2024 | — |
| 8-K |
Current report
Officer or director change
|
Feb 7, 2024 | Feb 7, 2024 |
| 8-K |
Current report
Auditor change
|
Jan 3, 2024 | Dec 27, 2023 |
| 8-K |
Current report
Officer or director change, Other events
|
Dec 7, 2023 | Dec 4, 2023 |
| 4 | Insider transaction | Nov 28, 2023 | Nov 24, 2023 |
| 10-Q | Quarterly report | Nov 20, 2023 | Sep 30, 2023 |
| NT 10-Q | Filing | Nov 14, 2023 | Sep 30, 2023 |
| EFFECT | Filing | Nov 8, 2023 | — |
| CORRESP | Letter to the SEC | Nov 6, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 3, 2023 | — |
| S-1 | Registration statement | Oct 31, 2023 | — |
| D | Filing | Oct 3, 2023 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Oct 3, 2023 | Sep 28, 2023 |
| 424B5 | Prospectus supplement | Oct 2, 2023 | — |
| 4 | Insider transaction | Sep 20, 2023 | Sep 15, 2023 |
| 4 | Insider transaction | Sep 19, 2023 | Sep 18, 2023 |
| 4 | Insider transaction | Sep 18, 2023 | Sep 15, 2023 |
| 8-K |
Current report
Officer or director change
|
Sep 6, 2023 | Aug 30, 2023 |
| 10-Q | Quarterly report | Aug 14, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 24, 2023 | Jul 24, 2023 |
| 8-K |
Current report
Material agreement
|
Jul 21, 2023 | Jul 21, 2023 |
| 424B5 | Prospectus supplement | Jul 21, 2023 | — |
| S-8 | Employee stock plan registration | Jul 14, 2023 | — |
| 8-K |
Current report
Shareholder vote results
|
Jun 22, 2023 | Jun 22, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 22, 2023 | May 22, 2023 |
| 10-Q | Quarterly report | May 12, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
May 10, 2023 | May 10, 2023 |
| ARS | Annual report to shareholders | Apr 28, 2023 | Dec 31, 2022 |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | Jun 22, 2023 |
| 10-K | Annual report | Apr 10, 2023 | Dec 31, 2022 |
| NT 10-K | Form nt 10-k | Apr 3, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Dec 16, 2022 | Dec 15, 2022 |
| DEF 14A | Proxy statement | Nov 21, 2022 | Dec 15, 2022 |
| D | Filing | Nov 15, 2022 | — |
| 10-Q | Quarterly report | Nov 14, 2022 | Sep 30, 2022 |
| PRE 14A | Preliminary proxy statement | Nov 9, 2022 | Dec 15, 2022 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change to shareholder rights, Bylaw or fiscal year change, Other events
|
Nov 9, 2022 | Nov 4, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 17, 2022 | Oct 17, 2022 |
| 10-Q | Quarterly report | Aug 15, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Aug 5, 2022 | Aug 5, 2022 |
| DEFA14A | Additional proxy material | Jul 26, 2022 | — |
| DEFA14A | Additional proxy material | Jul 25, 2022 | — |
| 3 | Initial insider ownership | Jul 20, 2022 | Jun 27, 2022 |
| 3 | Initial insider ownership | Jul 5, 2022 | Jun 27, 2022 |
| DEFA14A | Additional proxy material | Jun 30, 2022 | — |
| 8-K |
Current report
Officer or director change
|
Jun 28, 2022 | Jun 27, 2022 |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- HEPA (OTC), CTRVP (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Red Bank, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1583771
- Former names
- ContraVir Pharmaceuticals, Inc. (until Jul 23, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.